Recently, Professor Luo Guangbin, the core member of the innovative technology team of Shandong Association for the Prevention and Treatment of Cerebrovascular Diseases, led the "Lipogems ® The project of "Precision Treatment of Osteoarthritis by Technology" has been selected and selected at all levels, and has been shortlisted for the final of the "2022 National Disruptive Technology Innovation Competition". The project has stood out from thousands of competing projects across the country and won the final qualification after multiple rounds of screening.
This competition, hosted by the Ministry of Science and Technology of the People's Republic of China, focuses on technologies that may lead to major disruptive breakthroughs in the fields of integrated circuits, artificial intelligence, future networks and communications, biotechnology, new materials, green technology, high-end equipment manufacturing, and cross disciplines, Its purpose is to "tap the strategic, forward-looking and creative direction of subversive technology, promote subversive technological innovation and breakthrough, create a good ecology of subversive technological innovation in the whole society, promote China's original innovation ability and industrial competitiveness, and provide a powerful driving force for China's high-level scientific and technological self-reliance and high-quality economic development" (Excerpt from the announcement on the official website of the Ministry of Science and Technology of the People's Republic of China).
In the course of the competition, Professor Luo Guangbin led the team to submit a project related to the treatment of osteoarthritis based on autologous fat micro particles. After layer by layer competition, they won the ticket to the final and will compete with the top projects in various fields in China. Lipogems ® (Autologous fat microparticle technology) is a special treatment method for osteoarthritis, which is an extension of mesenchymal stem cell therapy technology. In this treatment, autologous adipose tissue is first extracted from patients with osteoarthritis, and then Lipogems ® The system is processed into injectable fat micro granular tissue, and finally the obtained fat micro granular tissue is injected into the injured part to treat the patient. Because the method of obtaining adipose tissue is simple and comes from its own adipose tissue, it is safe and cheap. The autologous fat microparticles contain rich three key elements of tissue regeneration and repair, including rich functional cells including pericytes and mesenchymal stem cells, three-dimensional biological scaffolds, exosomes and more than 100 kinds of cytokines. Therefore, they have strong antibacterial, anti-inflammatory, anti apoptotic, promoting vascular regeneration, and promoting tissue repair, In the treatment of osteoarthritis and diabetes foot ulcer healing have good effects. This treatment method was first applied in Europe and the United States. The innovative technology team introduced it to China as an exclusive agent in 2019, and carried out localization, iteration and upgrading.
Professor Luo Guangbin, the core member of the innovative science and technology team, is a doctor of the University of Illinois and a lifelong associate professor and doctoral supervisor of the Department of Genetics and Genomics of Case Western Reserve University School of Medicine; Distinguished professor of Beijing University of Traditional Chinese Medicine, director of Cancer Transformation Medical Center, doctoral supervisor and post doctoral supervisor; The work of cloning gene tags in mouse model using Sleeping Beauty transposon was creatively completed; He has won the National Science Fund for Overseas Distinguished Young Scientists, the Howard Temin Distinguished Young Scientist Award of the Cancer Center of the National Health Administration of the United States, the International March of Dimes Basil O'Connor Distinguished Young Scientist Award, and the Searle Distinguished Young Scientist Award of the United States; He has participated in the review of general and key projects of the National Health Administration, the National Guard and the National Army of the United States, and the National Natural Science Foundation of China for many times; As the first author or corresponding author in Nature, Human Mol. Genet, Mol. Biol. Cell，Mol. Cell. Biol., PNAS, Genes&Dev, Nature Genetics, etc. Efforts should be made to improve the original innovation ability and industrial competitiveness, and contribute to the realization of high-level scientific and technological self-reliance and high-quality economic development in China.
